We previously demonstrated that the use of a small molecule FABP4-specific inhibitor might be a novel therapeutic strategy against insulin resistance, type 2 diabetes mellitus and atherosclerosis [7]. Here, FABP4 is linked to type 2 diabetes mellitus.